Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients
|
|
- Annabella Boyd
- 5 years ago
- Views:
Transcription
1
2 Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients
3 Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried Forward Visit Baseline Week 6 Statistics N Mean Median (etc.) N Mean Median (etc.) p value (3) Active (N=xx) xx xx.x xx xx.x Observed Placebo (N=xx) xx xx.x xx xx.x Active (N=xx) xx xx.x x.xxxx Change from Baseline Placebo (N=xx) xx xx.x x.xxxx (1) ANOVA model: response = Treatment Group + Study Center. (2) ANCOVA model: change = Baseline + Treatment Group + Study Center. (3) Paired t test for change from baseline within Treatment Group. Treatment Group Comparison (p value) x.xxxx (1) x.xxxx (2)
4 Incidence Table 2. Incidence of Body Weight Loss, Baseline to Week 12 Visit / Outcome Statistics Active (N=xx) Placebo (N=xx) Week 12 Body Weight Loss No Body Weight Loss N (pct) xx (xxx.x) xx (xxx.x)
5 Correlations Table 3. Correlation Coefficients for Weight/BMI with Dietary Intake Change from Baseline to End of Study Change from Baseline to End of Study Active Correlation N Placebo Correlation N Weight (kg) Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index % of Calories from Carbohydrate (etc.)
6 SDTM Files Vital Signs: Height and Weight (VS) Food Frequency Questionnaire: dietary intake and analysis (QS)
7 SDTM Files: VS USUBJID VISIT VSTESTCD VSSTRESN VSSTAT BASELINE HEIGHT xx BASELINE WEIGHT xx WEEK 6 HEIGHT xx WEEK 6 WEIGHT xx WEEK 12 WEIGHT xx WEEK 12 HEIGHT. NOT DONE
8 SDTM Files: QS QSCAT = [name of questionnaire] QSSCAT QSTESTCD QSTEST QSORRES QSSTRESN VISIT Raw Questionnaire Response COLDCFR Cold cereal, Freq last wk 3 4 DAYS LAST WEEK 4 BASELINE Raw Questionnaire Response COLDCQU Cold cereal, Quan each 1 BOWL 2 BASELINE Dietary Analysis Dietary Analysis TOTCAL Total calories BASELINE CARB Carbohydrate BASELINE
9 Plan for ADaM File ADDIET Include nonmissing VSSTRESN, QSSTRESN Calculate BMI = [weight (kg)] / [height (m)] 2 Calculate percent of total calories from carbohydrate, fat, protein
10 Compute BMI AVISIT PARAMCD PARAMTYP SRCDOM SRCVAR SRCSEQ Baseline HEIGHT VS VSSTRESN xx Baseline WEIGHT VS VSSTRESN xx Baseline BMI DERIVED Week 6 HEIGHT VS VSSTRESN xx Week 6 WEIGHT VS VSSTRESN xx Week 6 BMI DERIVED
11 Compute PCTCARB AVISIT PARAMCD PARAMTYP SRCDOM SRCVAR SRCSEQ Baseline CARB QS QSSTRESN xx Baseline TOTCAL QS QSSTRESN xx Baseline PCTCARB DERIVED Week 6 CARB QS QSSTRESN xx Week 6 TOTCAL QS VSSTRESN xx Week 6 PCTCARB DERIVED
12 Parameters PARAM PARAMCD PARAMTYP Body Mass Index BMI DERIVED Carbohydrate (grams) CARB Height (cm) HEIGHT % of Calories from Carbohydrate PCTCARB DERIVED % of Calories from Fat PCTFAT DERIVED % of Calories from Protein PCTPROT DERIVED Total calories (kcal) TOTCAL Weight (kg) WEIGHT
13 Baseline flag AVISIT PARAMCD PARAMTYP ABLFL Baseline BMI DERIVED Y Baseline CARB Y Baseline HEIGHT Y Baseline PCTCARB DERIVED Y Baseline TOTCAL Y Baseline WEIGHT Y
14 Compute LOCF BMI AVISIT VISIT PARAMCD PARAMTYP DTYPE SRCDOM SRCVAR SRCSEQ Baseline BASELINE BMI DERIVED Week 6 WEEK 6 BMI DERIVED Week 12 WEEK 6 BMI DERIVED LOCF
15 Average Over Visits AVISIT PARAMCD PARAMTYP DTYPE SRCDOM SRCVAR SRCSEQ Post Baseline CARB AVERAGE Post Baseline PCTCARB DERIVED AVERAGE Post Baseline TOTCAL AVERAGE
16 Dietary Parameters AVISIT PARAMCD PARAMTYP DTYPE SRCDOM SRCVAR SRCSEQ Baseline CARB QS QSSTRESN xx Baseline TOTCAL QS QSSTRESN xx Baseline PCTCARB DERIVED Week 6 CARB QS QSSTRESN xx Week 6 TOTCAL QS QSSTRESN xx Week 6 PCTCARB DERIVED Week 12 CARB QS QSSTRESN xx Week 12 TOTCAL QS QSSTRESN xx Week 12 PCTCARB DERIVED Post Baseline CARB AVERAGE Post Baseline PCTCARB DERIVED AVERAGE Post Baseline TOTCAL AVERAGE
17 AVAL, BASE, CHG AVISIT PARAMCD AVAL BASE CHG ABLFL Baseline BMI x.x x.x Y Baseline HEIGHT x.x x.x Y Baseline CARB x.x x.x Y Baseline TOTCAL x.x x.x Y Baseline PCTCARB x.x x.x Y Baseline WEIGHT x.x x.x Y Week 6 BMI x.x x.x x.x Week 6 HEIGHT x.x x.x x.x Week 6 CARB x.x x.x x.x Week 6 TOTCAL x.x x.x x.x Week 6 PCTCARB x.x x.x x.x Week 6 WEIGHT x.x x.x x.x
18 Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried Forward Visit Baseline Week 6 Statistics N Mean Median (etc.) N Mean Median (etc.) p value (3) Active (N=xx) xx xx.x xx xx.x Observed Placebo (N=xx) xx xx.x xx xx.x Active (N=xx) xx xx.x x.xxxx Change from Baseline Placebo (N=xx) xx xx.x x.xxxx (1) ANOVA model: response = Treatment Group + Study Center. (2) ANCOVA model: change = Baseline + Treatment Group + Study Center. (3) Paired t test for change from baseline within Treatment Group. Treatment Group Comparison (p value) x.xxxx (1) x.xxxx (2)
19 Results Metadata: Table 1 Display Identifier: Table 1 Display Name: Table 1. Body Mass Index using Last Observation Carried Forward Result Identifier Param Paramcd Analysis Variable Dataset Selection Criteria Documentation Programming Statements (SAS ) Observed baseline Treatment Group Comparison p value Body Mass Index BMI AVAL ADDIET AVISITN = 0 and ITTFL = Y Use Type III sums of squares for all models, and pooled site number proc glm; class trtpn sitegr1n; model aval = trtpn sitegr1n; Observed postbaseline LS means Body Mass Index BMI AVAL ADDIET AVISITN > 0 and ITTFL = Y proc glm; by avisitn; class trtpn sitegr1n; model aval = base trtpn sitegr1n; lsmeans trtpn;
20 Results Metadata: Table 1 Display Identifier: Table 1 Display Name: Table 1. Body Mass Index using Last Observation Carried Forward Result Identifier Param Paramcd Analysis Variable Dataset Selection Criteria Document ation Programming Statements (SAS ) Change LS means and Treatment Group Comparison p value (footnote 2) Body Mass Index BMI CHG ADDIET AVISITN > 0 and ITTFL = Y Model with no interaction terms proc glm; by avisitn; class trtpn sitegr1n; model chg = base trtpn sitegr1n; lsmeans trtpn; p value (footnote 3) Body Mass Index BMI CHG ADDIET AVISITN > 0 and ITTFL = Y Paired t test proc means prt nway; class avisitn trtpn; var chg;
21 Categorize Weight Change AVISIT PARAMCD AVAL BASE CHG CHGCAT1 Baseline WEIGHT x.x x.x Week 6 WEIGHT x.x x.x 1.3 Body Weight Loss Week 12 WEIGHT x.x x.x 0.9 No Body Weight Loss
22 Incidence Table 2. Incidence of Body Weight Loss, Baseline to Week 12 Visit / Outcome Statistics Active (N=xx) Placebo (N=xx) Week 12 Body Weight Loss No Body Weight Loss N (pct) xx (xxx.x) xx (xxx.x)
23 Results Metadata: Table 2 Display Identifier: Table 2 Display Name: Incidence of Body Weight Loss, Baseline to Week 12 Result Identifier Param Paramcd Analysis Variable Weight (kg) Dataset Selection Criteria Documentation Programming Statements (SAS ) WEIGHT CHGCAT1 ADDIET ITTFL = Y and CHGCAT1N in (1,2) and AVISIT = Week 12 CHGCAT1N = 1 means body weight loss, 2 = no body weight loss.
24 Correlations Table 3. Correlation Coefficients for Weight/BMI with Dietary Intake Change from Baseline to End of Study Change from Baseline to End of Study Active Correlation N Placebo Correlation N Weight (kg) Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index % of Calories from Carbohydrate (etc.)
25 Correlations: tasks Only visits where all parameters were measured (no LOCF) Change from baseline to last such postbaseline visit
26 All values measured Flag visits where all parameters measured Easy when denormalized: if nmiss(height,weight,carb,totcal) = 0 then ANL01FL = Y ; AVISIT HEIGHT WEIGHT TOTCAL CARB ANL01FL Baseline x.x x.x x.x x.x Y Week 6 x.x x.x x.x x.x Y
27 All values measured Then transpose: AVISIT PARAMCD CHG ABLFL ANL01FL Baseline CARB Y Y Baseline HEIGHT Y Y Baseline TOTCAL Y Y Baseline WEIGHT Y Y Week 6 CARB x.x Y Week 6 HEIGHT x.x Y Week 6 TOTCAL x.x Y Week 6 WEIGHT x.x Y
28 Last visit with all measured AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL Baseline CARB Y Y Baseline HEIGHT Y Y Baseline TOTCAL Y Y Baseline WEIGHT Y Y Week 6 CARB x.x Y Week 6 HEIGHT x.x Y Week 6 TOTCAL x.x Y Week 6 WEIGHT x.x Y Week 12 CARB x.x Y Y Week 12 HEIGHT x.x Y Y Week 12 TOTCAL x.x Y Y Week 12 WEIGHT x.x Y Y
29 All measured at baseline AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL ANL03FL Baseline CARB Y Y Y Baseline HEIGHT Y Y Y Baseline TOTCAL Y Y Y Baseline WEIGHT Y Y Y Week 6 CARB x.x Y Y Week 6 HEIGHT x.x Y Y Week 6 TOTCAL x.x Y Y Week 6 WEIGHT x.x Y Y Week 12 CARB x.x Y Y Y Week 12 HEIGHT x.x Y Y Y Week 12 TOTCAL x.x Y Y Y Week 12 WEIGHT x.x Y Y Y
30 All not measured at baseline AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL ANL03FL Baseline CARB Y Baseline TOTCAL Y Baseline WEIGHT Y Week 6 CARB x.x Y Week 6 HEIGHT x.x Y Week 6 TOTCAL x.x Y Week 6 WEIGHT x.x Y Week 12 CARB x.x Y Y Week 12 HEIGHT x.x Y Y Week 12 TOTCAL x.x Y Y Week 12 WEIGHT x.x Y Y
31 Record Selection ANL02FL = Y AND ANL03FL = Y AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL ANL03FL Week 12 CARB x.x Y Y Y Week 12 HEIGHT x.x Y Y Y Week 12 TOTCAL x.x Y Y Y Week 12 WEIGHT x.x Y Y Y
32 In SAS proc sort data=addiet out=tabledata; by trtp usubjid paramcd; where anl02fl = Y and anl03fl = Y ; run; proc transpose data=tabledata out=trandata; by trtp usubjid; id paramcd; var chg; run; proc corr data=trandata pearson; by trtp; var weight bmi; with totcal carb (other parameters); run;
33 Record Selection (actual) proc sql; create table main as select usubjid, trtpn, paramcd, chg from adam.addiet where ittfl = Y and anl03fl = Y and ( (avisit = Post Baseline and paramcd in ( TOTCAL, CARB, )) or (paramcd in ( BMI, WEIGHT ) and anl02fl = Y ) ) order by trtpn, usubjid, paramcd; quit;
34 Analysis File Metadata Dataset Description Structure Purpose Keys Class of Dataset ADDIET Diet and weight analysis file One record per subject per parameter per analysis visit Analysis STUDYID, USUBJID, PARAMCD, AVISIT BDS Location addiet.xpt
35 Bonus Example! VS Toxicity Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials Fever Vital Signs Tachycardia beats per minute Bradycardia beats per minute Hypertension (systolic) mm Hg Hypertension (diastolic) mm Hg Hypotension (systolic) mm Hg Respiratory rate breaths per minute Mild (Grade 1) C F Moderate (Grade 2) C F > < > > <80 Severe (Grade 3) C F >40 C >104 F >25 Intubation Potentially Life Threatening (Grade 4) ER visit or hospitalization for arrhythmia ER visit or hospitalization for arrhythmia ER visit or hospitalization for malignant hypertension ER visit or hospitalization for malignant hypertension ER visit or hospitalization for hypotensive shock
36 VS Toxicity Shift Table N (%) with No increase Increase by 1 grade Increase by 2 grades Increase by 3 grades Increase by 4 grades (only possible with Fever based on vital signs alone)
37 ADVS Design Approach: ATOXGR, BTOXGR: Assign toxicity grade AVALCAT1, BASECAT1: Categorize results into Normal, Fever, Tachycardia, Bradycardia, Hypertension (systolic), etc. Ranges for both dependent on PARAMCD SHIFT1: Assign shift as No increase, Increase by 1 grade, Increase by 2 grades, etc.
38 ADVS Design For systolic blood pressure: (row) USUBJID PARAMCD AVISIT AVAL ATOXGR AVALCAT SYSBP Baseline Normal SYSBP Week Hypertension (systolic) SYSBP Baseline Normal SYSBP Week Hypotension (systolic) (row) BASE BTOXGR BASECAT1 SHIFT1 SHIFT1N ABLFL Normal Y Normal Increase by 1 grade Normal Y Normal Increase by 3 grades 3
39 ADVS Design The shift is based on ATOXGR, BTOXGR without reference to type of toxicity Use AVALCAT1 to select type of toxicity where PARAMCD = SYSBP and SHIFT1 ne and AVALCAT1 in ( Normal, Hypertension (systolic) ); where PARAMCD = TEMP and SHIFT1 ne and AVALCAT1 in ( Normal, Fever );
40 Karen G. Malley Malley Research Programming, Inc. Tel:
Frequency Tables Aspects to Consider / PhUSE - Industry Starters / Katja Glaß
Frequency Tables Aspects to Consider 15.10.2014 / PhUSE - Industry Starters / Katja Glaß Agenda Introduction Do the double programming Demography Adverse Events Laboratory Summary and further aspects Page
More informationCDISC Journey in Solid Tumor using RECIST 1.1. Kevin Lee Statistician/CDISC Consultant/Programmer
CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee Statistician/CDISC Consultant/Programmer Disclaimer Any views or opinions presented in this presenta1on are solely those of the author and do not
More informationStandard Methods for Analysis and Reporting of VAS or NRS Derived Pain Relief Response Scores
Standard Methods for Analysis and Reporting of VAS or NRS Derived Pain Relief Response Scores James R. Johnson, PhD Sr. Director Biostatistics and Data Sciences Flexion Therapeutics, Inc. Presentation
More informationADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go?
ABSTRACT PharmaSUG 2017 - Paper DS17 ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? Jack Shostak, Duke Clinical Research Institute ADaM has variables that allow you to cluster,
More informationMichigan Neuropathy Screening Instrument (MNSI)
Michigan Neuropathy Screening Instrument () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationHospital Anxiety and Depression Scale (HADS)
Hospital Anxiety and Depression Scale (HADS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and
More informationClinical Global Impression (CGI)
Clinical Global Impression (CGI) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationEpworth Sleepiness Scale (ESS)
Epworth Sleepiness Scale (ESS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaires Sub-team Notes to Readers This
More informationNeuropathic Pain Scale (NPS)
Neuropathic Pain Scale (NPS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and the CDISC Questionnaire
More informationColumbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)
Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial
More informationLet s Create Standard Value Level Metadata
PRA Health Sciences PhUSE US Connect 2019 Paper DS12 February 27, 2019 David Fielding Value Level Metadata Value Level Metadata is an important part of the Define-XML that allows us to explain our study
More informationModified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0
Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v2.0 Team
More informationGraph Display of Patient Profile Using SAS
PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile
More informationBarnes Akathisia Rating Scale (BARS)
Barnes Akathisia Rating Scale () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes to Readers This
More informationBrief Psychiatric Rating Scale-Anchored (BPRS-A)
Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes
More informationColumbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)
Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial
More informationDisability Assessment for Dementia (DAD)
Disability Assessment for Dementia (DAD) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v1.1 Team and the CDISC Questionnaire
More informationShort-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2)
Short-Form McGill Pain Questionniare-2 ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationColumbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)
Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial
More informationBrief Psychiatric Rating Scale-Anchored (BPRS-A)
Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes
More informationPain Relief (PR) Notes to Readers
Pain (PR) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations, Innovations, Opportunities,
More informationADaM Tips for Exposure Summary
ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary
More informationPROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables
PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep
More informationCDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee PhUSE conference Oct 14th, 2013
CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee PhUSE conference Oct 14th, 2013 Disclaimer Any views or opinions presented in this presentation are solely those of the author and do not necessarily
More informationHamilton Depression Rating Scale 17-Item (HAMD 17)
Hamilton Depression Rating Scale -Item ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationAnalysis Datasets for Baseline Characteristics and Exposure Time for Multi-stage Clinical Trials
Analysis Datasets for Baseline Characteristics and Exposure Time for Multi-stage Clinical Trials Kim Umans, Katherine Riester, Manjit McNeill, Wei Liu, and Lukasz Kniola PhUSE 2016, CD06, Barcelona Introduction
More informationIntegrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research
Integrated ADSL PhUSE 2012-10-17 Nate Freimark/Thomas Clinch Theorem Clinical Research ADSL - Not Without Challenges Where to Begin Source Data One ADSL or Two Number of Records per Subject Update or Create
More informationAE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.
PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables
More informationA SAS sy Study of ediary Data
A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)
More informationStatistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue
STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationImputing Dose Levels for Adverse Events
Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationDesign and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies
PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationSummary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ
CT Registry ID#4668 Page 1 Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ Date summary approved by Lilly: 09 August 2005 Title of Study: Safety and Efficacy of Atomoxetine or Atomoxetine Plus
More informationPharmaceutical Applications
Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients
More informationOCCDS Creating flags or records. Rob Wartenhorst PhUSE Barcelona 2016
OCCDS Creating flags or records Rob Wartenhorst PhUSE Barcelona 2016 Introduction ADAE, ADCM and ADMH originally set up using ADAE structure. After release of OCCDS guide attempted to implement the occurrence
More informationStat Wk 9: Hypothesis Tests and Analysis
Stat 342 - Wk 9: Hypothesis Tests and Analysis Crash course on ANOVA, proc glm Stat 342 Notes. Week 9 Page 1 / 57 Crash Course: ANOVA AnOVa stands for Analysis Of Variance. Sometimes it s called ANOVA,
More informationEVERY DAY A GUIDE TO KNOW YOUR NUMBERS
EVERY DAY A GUIDE TO KNOW YOUR NUMBERS WHAT IS BMI? Measuring your Body Mass Index (BMI) is a useful way to determine if you are at a healthy weight. Excess weight can increase your risk of heart disease,
More informationADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc.
ADaM Considerations and Content in the TA User Guides Susan J Kenny, PhD Maximum Likelihood, Inc. Topics to Discuss Focus of ADaM content Overview of TAUGs with ADaM content Specific ADaM content in selected
More informationLinear Regression in SAS
1 Suppose we wish to examine factors that predict patient s hemoglobin levels. Simulated data for six patients is used throughout this tutorial. data hgb_data; input id age race $ bmi hgb; cards; 21 25
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYAX
CT Registry ID#5004 Page 1 Summary ID# 5004 Clinical Study Summary: Study B4Z-MC-LYAX A Randomized, Double-Blind, Placebo-Controlled Study of Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationInformation Sheet. Weight. Accessible information about weight for adults with an eating disorder
Information Sheet Weight Accessible information about weight for adults with an eating disorder ? Why do I need to restore my body weight? Weight restoration in eating disorders is integral to recovery
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationUsing Direct Standardization SAS Macro for a Valid Comparison in Observational Studies
T07-2008 Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies Daojun Mo 1, Xia Li 2 and Alan Zimmermann 1 1 Eli Lilly and Company, Indianapolis, IN 2 inventiv Clinical
More informationA study of academic stress and its effect on vital parameters in final year medical students at SAIMS Medical College, Indore, Madhya Pradesh
Biomedical Research 2011; 22 (3): 361-365 A study of academic stress and its effect on vital parameters in final year medical students at SAIMS Medical College, Indore, Madhya Pradesh Balkishan Sharma,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL The effect of current dietary provided by frequent advice versus food delivery on weight loss and cardiovascular risk factors. A Randomized Clinical Trial. David JA Jenkins, Beatrice
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBR
CT Registry ID#6934 Page 1 Summary ID# 6934 Clinical Study Summary: Study B4Z-MC-LYBR Title of Study: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate
More informationPATIENT INFORMATION. Medicine To Treat: H ypertension. Patient Awareness and Self-Care
PATIENT INFORMATION Medicine To Treat: H ypertension Patient Awareness and Self-Care WHAT IS BLOOD PRESSURE AND HIGH BLOOD PRESSURE? Blood pressure is the force generated as your heart pumps blood and
More informationNOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet
NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet FASTING 16 hours a day EXCERCISE 150 min a week DIET Low carb NOSM Northern Research Conference, Kenora, 2018 R Minty, T O Driscoll, L Kelly,
More informationSample Resting Metabolic Rate Test Results
Sample Resting Metabolic Rate Test Results Innerscan Results Date: Sample Height (CM) 183 Weight (Kg) 89.3 Body Fat (%) 24.3 Body Water (%) 51.4 Muscle Mass (Kg) 64.3 Bone Mass (Kg) 3.3 Physique Rating
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationHungry Mice. NP: Mice in this group ate as much as they pleased of a non-purified, standard diet for laboratory mice.
Hungry Mice When laboratory mice (and maybe other animals) are fed a nutritionally adequate but near-starvation diet, they may live longer on average than mice that eat a normal amount of food. In this
More informationDigestive Project Part 1
Digestive Project Part 1 Purpose: For Part 1 of the Digestive System project you will be researching various minerals and vitamins that are essential for the body. Background Info. 1. What is the difference
More informationSUPPLEMENTARY DATA. Supplementary Methods
Supplementary Methods Chronic kidney disease stage 4 or 5 Current diabetic foot with ulcer, soft tissue infection or necrosis Unstable angina, myocardial infarction, or cerebrovascular accident over the
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More informationImplementing Patient Report Outcome Data in Clinical Trials Analysis
PharmaSUG 2017 - Paper PO04 Implementing Patient Report Outcome Data in Clinical Trials Analysis ABSTRACT Qi Wang, Amgen, Thousand Oaks, CA Over the recent decades, Health-Related Quality of Life (HRQoL)
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationIntro to SPSS. Using SPSS through WebFAS
Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationRICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT Carmarthenshire County Council
RICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT 2016 Carmarthenshire County Council WHY LEAD A HEALTHY LIFESTYLE? A nutritious, well-balanced diet along with physical activity and refraining from smoking
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationa) Vitality Compass Life Expectancy
PGCE: LIFE ORIENTATION LEARNING AREA STUDIES COURSE OUTLINE 2017 GET Health & Wellness Workbook Created by Desiree Lee http://loilifeo.weebly.com/ All lectures and links and notes are available on this
More informationChapter 6 Measures of Bivariate Association 1
Chapter 6 Measures of Bivariate Association 1 A bivariate relationship involves relationship between two variables. Examples: Relationship between GPA and SAT score Relationship between height and weight
More informationChapter 9 Vital Signs and SAMPLE History DOT Directory
Chapter 9 Vital Signs and SAMPLE History U.S. Objectives U.S. Objectives are covered and/or supported by the PowerPoint Slide Program and Notes for Emergency Care, 11th Ed. Please see the Chapter 9 correlation
More informationHIGH ENERGY AND FAT INTAKE BETWEEN DORMITORY AND NON-DORMITORY STUDENTS IN CHULALONGKORN UNIVERSITY, THAILAND
HIGH ENERGY AND FAT INTAKE BETWEEN DORMITORY AND NON-DORMITORY STUDENTS IN CHULALONGKORN UNIVERSITY, THAILAND Patimanukaseam P, Punya-ngarm Y. Department of Biochemistry, Faculty of Dentistry, Chulalongkorn
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSupplementary Online Content
Supplementary Online Content Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized
More informationPharmaSUG 2018 Paper AD-02
PharmaSUG 2018 Paper AD-02 Derivations of Response Status from SDTM Domains using RECIST 1.1 Christine Teng, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ USA Pang Lei, Merck Research Laboratories,
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationLindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine
Lindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine Acknowledgments Robin Masheb, PhD Carlos Grilo, PhD Barbara Rolls, PhD Diane Mitchell, MS, RD No conflicts of interest
More informationUnified Parkinson's Disease Rating Scale UPDRS
Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological
More informationStandards for Analyzable Submission Datasets for Directed Safety Analyses
Standards for Analyzable Submission Datasets for Directed Safety Analyses Michael Nessly Director, Clinical Biostatistics Merck Research Labs CDISC Analysis Dataset Models Team (ADaM) nesslym@merck.com
More informationPaper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ
Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps
More informationWho is Exante Diet suitable for?
Who is Exante Diet suitable for? www.exantediet.com Who is Exante Diet Suitable For? Exante Diet has a programme for almost everyone. Whether you re looking to lose 2lbs or 10 stone, you can do it with
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationHome Food Resources for You Consumers. Food
Home Food Resources for You Consumers Food How to Understand and Use the Nutrition Facts Label On this page: The Nutrition Facts Panel - An Overview The Serving Size Calories (and Calories from Fat) The
More informationUNIVERSIDAD*DE*COSTA*RICA*
* * * UNIVERSIDAD*DE*COSTA*RICA* CRELES*Pre21945* Costa*Rican*Longevity*and*Healthy*Aging*Study* Recoded*Variables,*Wave*1* Luis*Rosero2Bixby* William*H.*Dow* Xinia*Fernández* Coverage:Costa*Rica,*population*aged*60+*in*2005*
More informationBCH 445 Biochemistry of nutrition Dr. Mohamed Saad Daoud
BCH 445 Biochemistry of nutrition Dr. Mohamed Saad Daoud 1 Energy Needs & Requirements Food is the only source of body which undergoes Metabolism and liberate / Generates Energy required for vital activities
More informationClinical Study Report. Arbonne Essentials Products Arbonne Evolution Products
Clinical Study Report Arbonne Essentials Products Arbonne Evolution Products CLINICAL STUDY A 16 week study assessing the effect of dietary supplements and recommended calorie restrictions and regular,
More informationThings you need to know about the Normal Distribution. How to use your statistical calculator to calculate The mean The SD of a set of data points.
Things you need to know about the Normal Distribution How to use your statistical calculator to calculate The mean The SD of a set of data points. The formula for the Variance (SD 2 ) The formula for the
More informationTable S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group
Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,
More informationAnalysis of Oncology Studies for Programmers and Statisticians
PharmaSUG 2018 DS06 Analysis of Oncology Studies for Programmers and Statisticians Kevin Lee, Clindata Insight, Moraga, CA ABSTRACT Compared to other therapeutic studies, oncology studies are generally
More informationP105 STUDY REPORT A Double Blind Placebo Controlled Trial of the Effect of AppTrim
P105 STUDY REPORT A Double Blind Placebo Controlled Trial of the Effect of AppTrim on Appetite Suppression and Obesity Management Targeted Medical Pharma Inc. 1 6/9/2011 12:41 PM Executive Summary Study
More informationPharmaSUG Paper SP01
PharmaSUG 2014 - Paper SP01 Factor Analysis of Scale for Assessment of Negative Symptoms using SAS Software Ben Adeyi, Shire Pharmaceuticals, Chesterbrook, PA David Shen, Independent Consultant, Chesterbrook,
More information